UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel

Clinical cancer research, 2017-04, Vol.23 (8), p.1945-1954

2017

Volltextzugriff (PDF)

High-Throughput Virtual Screening Identifies Novel N′‑(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors

Journal of medicinal chemistry, 2013-12, Vol.56 (23), p.9496-9508

2013

Volltextzugriff (PDF)

Targeting Axl and Mer kinases in cancer

Molecular cancer therapeutics, 2011-10, Vol.10 (10), p.1763-1773

2011

Volltextzugriff (PDF)

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer

PloS one, 2020-07, Vol.15 (7), p.e0235705

2020

Volltextzugriff (PDF)

Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents

Molecules (Basel, Switzerland), 2020-02, Vol.25 (3), p.645

2020

Volltextzugriff (PDF)

SIK2 Restricts Autophagic Flux To Support Triple-Negative Breast Cancer Survival

Molecular and cellular biology, 2016-12, Vol.36 (24), p.3048-3057

2016

Volltextzugriff (PDF)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

The Journal of clinical investigation, 2022-06, Vol.132 (11), p.1-20

2022

Volltextzugriff (PDF)

Ligand‐based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase

Molecular informatics, 2022-01, Vol.41 (1), p.e2000181-n/a

2022

Volltextzugriff (PDF)

S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth

Molecular cancer therapeutics, 2010-05, Vol.9 (5), p.1443-1450

2010

Volltextzugriff (PDF)

870 Targeting GCN2 kinase-driven stress response inactivation to restore tumor immunity in metastatic triple negative breast cancer

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A911-A911

2021

Volltextzugriff (PDF)

Use of a bacteriophage lysin to identify a novel target for antimicrobial development

PloS one, 2013-04, Vol.8 (4), p.e60754-e60754

2013

Volltextzugriff (PDF)

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity

BioMed research international, 2014-01, Vol.2014 (2014), p.1-13

2014

Volltextzugriff (PDF)

Chemical Genetic Screen Reveals a Role for Desmosomal Adhesion in Mammary Branching Morphogenesis

The Journal of biological chemistry, 2013-01, Vol.288 (4), p.2261-2270

2013

Volltextzugriff (PDF)

Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach

Molecular cancer therapeutics, 2006-07, Vol.5 (7), p.1764-1773

2006

Volltextzugriff (PDF)

Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease

Bioorganic & medicinal chemistry letters, 2017-07, Vol.27 (13), p.2962-2966

2017

Volltextzugriff (PDF)

Development of BLX-3030, a potent and selective inhibitor of CDK9 for the treatment of NMYC-driven NEPCS

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17067-e17067

2023

Volltextzugriff (PDF)

Abstract LB136: Targeting GCN2 kinase-driven stress response inactivation by orally available small molecules to restore immune tumor microenvironment in prostate cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.LB136-LB136

2021

Volltextzugriff (PDF)

Abstract 4587: Development of highly selective, potent, orally available PIM1 inhibitor BLX0631 shows a therapeutics potential in multiple myeloma models

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.4587-4587

2024

Volltextzugriff (PDF)

Design, Synthesis, and Evaluation of Psorospermin/Quinobenzoxazine Hybrids as Structurally Novel Antitumor Agents

Journal of medicinal chemistry, 2003-07, Vol.46 (14), p.2958-2972

2003

Volltextzugriff (PDF)

Abstract 1333: Evaluation of a novel PELP1 inhibitor for treatment of triple negative breast cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1333-1333

2021

Volltextzugriff (PDF)

Abstract PS17-15: Targeting the PELP1 axis for treating ESR1 mutant driven breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS17-15-PS17-15

2021

Volltextzugriff (PDF)

A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma

Journal of molecular medicine (Berlin, Germany), 2013-04, Vol.91 (4), p.507-512

2013

Volltextzugriff (PDF)

A computational study of structural differences of binding of NADP+ and G6P substrates to G6PD Mediterraneanc.563T, G6PD A−c.202A/c.376G, G6PD Cairoc.404C and G6PD Gazac.536A mutations

Blood cells, molecules, & diseases, 2021-07, Vol.89, p.102572-102572, Article 102572

2021

Volltextzugriff (PDF)

Abstract 3869: The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3869-3869

2019

Volltextzugriff (PDF)

Abstract 5210: Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5210-5210

2020

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(90)

Publikationsform

Artikel
(102)

Sprache

Englisch
(102)

Erscheinungsjahr

n.n

Thema

Science & Technology
(44)
Life Sciences & Biomedicine
(32)
Humans
(27)
Chemistry
(16)
Physical Sciences
(16)
Animals
(15)
Cell Line, Tumor
(15)
Pharmacology & Pharmacy
(13)
Chemistry, Medicinal
(12)
Mice
(12)
Chemistry, Organic
(11)
Female
(11)
Models, Molecular
(10)
Oncology
(9)
Structure-Activity Relationship
(9)
Kinases
(8)
Antineoplastic Agents - Pharmacology
(7)
Drug Design
(7)
Enzyme Inhibitors - Pharmacology
(7)
Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel

High-Throughput Virtual Screening Identifies Novel N′‑(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors

Targeting Axl and Mer kinases in cancer

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer

Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents

SIK2 Restricts Autophagic Flux To Support Triple-Negative Breast Cancer Survival

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

Ligand‐based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase

S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth

870 Targeting GCN2 kinase-driven stress response inactivation to restore tumor immunity in metastatic triple negative breast cancer

Use of a bacteriophage lysin to identify a novel target for antimicrobial development

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity

Chemical Genetic Screen Reveals a Role for Desmosomal Adhesion in Mammary Branching Morphogenesis

Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach

Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease

Development of BLX-3030, a potent and selective inhibitor of CDK9 for the treatment of NMYC-driven NEPCS

Abstract LB136: Targeting GCN2 kinase-driven stress response inactivation by orally available small molecules to restore immune tumor microenvironment in prostate cancers

Abstract 4587: Development of highly selective, potent, orally available PIM1 inhibitor BLX0631 shows a therapeutics potential in multiple myeloma models

Design, Synthesis, and Evaluation of Psorospermin/Quinobenzoxazine Hybrids as Structurally Novel Antitumor Agents

Abstract 1333: Evaluation of a novel PELP1 inhibitor for treatment of triple negative breast cancer

Abstract PS17-15: Targeting the PELP1 axis for treating ESR1 mutant driven breast cancer

A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma

A computational study of structural differences of binding of NADP+ and G6P substrates to G6PD Mediterraneanc.563T, G6PD A−c.202A/c.376G, G6PD Cairoc.404C and G6PD Gazac.536A mutations

Abstract 3869: The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT)

Abstract 5210: Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors

Suchergebnisse filtern